The Conversation (0)
July 31, 2025
Sign up to get your FREE
Cardiex Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
05 December 2024
Cardiex Limited
Biomarker technologies and digital solutions to address the world’s largest health disorders. Keep Reading...
29 August 2025
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
29 August 2025
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Activities Report
Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
24 June 2025
Results of Entitlement Offer
Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
05 June 2025
Offer Booklet - Non-Renounceable Entitlement Offer
Cardiex Limited (CDX:AU) has announced Offer Booklet - Non-Renounceable Entitlement OfferDownload the PDF here. Keep Reading...
13 January
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2... Keep Reading...
01 January
Inside the ASX Biotech Boom: What’s Fuelling the Next Wave
Australia’s healthcare and biotechnology sector has matured into one of the most promising and strategically important segments of the ASX. Fortunes can shift on a single clinical trial result. A company with no revenue today could be a global contender tomorrow — if its science holds up. As... Keep Reading...
22 December 2025
Hanlim & Korean Government Fund Pathway to Clinical Trial
Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
02 December 2025
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
01 December 2025
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven... Keep Reading...
13 November 2025
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's... Keep Reading...
Latest News
Sign up to get your FREE
Cardiex Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00